Statins Use in Veterans With Peripheral Artery Disease: Insights From the PEARLS Study
Authors:
- Rohit NathaniRNRohit Nathani
- Mary S. Vaughan-SarrazinMVMary S. Vaughan-Sarrazin
- Mohammad A. Al-GaradiMAMohammad A. Al-Garadi
- Kim G. SmolderenKSKim G. Smolderen
- Shirling TsaiSTShirling Tsai
- Shipra AryaSAShipra Arya
- Joshua A. BeckmanJBJoshua A. Beckman
- Brian C. LundBLBrian C. Lund
- Saket GirotraSGSaket Girotra
- 1 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (10)
Abstract
BACKGROUND: Guidelines recommend high-intensity statins in patients with peripheral artery disease (PAD). We examined contemporary use of statins among real-world patients with a new diagnosis of PAD. METHODS: Within a national registry of Veterans with incident PAD, we used pharmacy claims data to determine active statin use within 1 year of PAD diagnosis. We also used laboratory data to evaluate lipid levels. Hierarchical multivariable logistic regression was used to identify variables associated with the use of any statin and high-intensity statin 1 year after PAD diagnosis and quantify variation in statin use across sites. RESULTS: Among 91 970 patients with PAD alive at 1 year, the median age was 70 years, 97.2% were men, and 18.6% were Black. At 1 year, 64 231 (69.9%) patients were on a statin, and 34 017 (37.0%) were on a high-intensity statin. Among nonstatin users, 53.4% (14 834/27 739) had not been prescribed a statin at any time in the preceding 3 years. Overall, the median low-density lipoprotein cholesterol was 81.6 mg/dL and was lower in those on high-intensity statins versus low/moderate-intensity statins versus no statins (72.2 versus 78.0 versus 100 mg/dL). Age, prior history of coronary artery disease, cerebrovascular disease, hypertension, diabetes, and current or former smoking history, obesity, and revascularization during the initial 6 months were associated with higher statin and high-intensity statin use (among statin users). At the site level, there was modest variation in statin use, especially high-intensity statins, which ranged from 20% to 54% with an overall median odds ratio of 1.39 (95% CI, 1.32–1.46). CONCLUSIONS: Nearly 70% of patients with PAD were receiving a statin within 1 year of PAD diagnosis. However, use of high-intensity statins and nonstatin lipid-lowering therapy remained suboptimal. Moreover, there was modest variation in use of statins, especially high-intensity statins, across sites, highlighting opportunities for improving guideline-concordant care in patients with PAD.Keywords
This publication has 42 references indexed in Scilit:
- Health Insurance Enrollment Among US Veterans, 2010-2021JAMA Network Open, 2024
- Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care NetworkJAMA Cardiology, 2023
- Prescribing of Statins After Lower Extremity Revascularization Procedures in the USJAMA Network Open, 2021
- Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No TreatmentJACC, 2021
- Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery DiseaseJACC, 2020
- Validity of Peripheral Arterial Disease Diagnoses in the Danish National Patient RegistryEuropean Journal of Vascular and Endovascular Surgery, 2017
- Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial IndexJACC, 2016
- Influence of Race on the Management of Lower Extremity IschemiaJAMA Surgery, 2013
- Multilevel modelling of medical dataStatistics in Medicine, 2002
- Decreased Ankle/Arm Blood Pressure Index and Mortality in Elderly WomenJAMA, 1993